USP797: Environmental Testing Plan John Sullivan, Pharm. D. April 11 th, 2015 ISHP Spring Conference

Similar documents
ENVIRONMENTAL MONITORING

Everything you want to know about USP 797

USP <797> Cleanroom Design and Environmental Monitoring. Andrew King, USP <797> Specialist CETA Member RCCP-SC

Understanding USP 797

Environmental Monitoring

Hazardous Drug. Cleanroom. Standards

The Microbial Bioburden of USP 797 Compliance. Simplifying Environmental Quality and Control Practices for Pharmaceutical Compounding

Environmental Monitoring of Clean Rooms

Environmental Monitoring

Qualification of an Environmental Monitoring Program

ASHP Guidelines on Compounding Sterile Preparations

Rules for Compounded Sterile Preparations (CSPs)

FDA and the Compounding Pharmacy

Hand and Glove Hygiene Keys to Safe Compounding

Risk-Based Environmental Monitoring. Marsha Stabler Hardiman Senior Consultant Concordia ValSource Wednesday September 17, 2014 FDA/PQRI

AMENDED January 27, 2015

Particle Monitoring Requirements in Pharmaceutical Cleanrooms

New Mexico Register / Volume XXVI, Number 5 / March 16, 2015

BRIEFING 797 Pharmaceutical Compounding Sterile Preparations,

Sample Pharmacy CLEANING AND SANITIZING PROCEDURE P-304.1

Cleaning. By the end of this chapter, you will be able to: Introduction. Definitions. Chapter 9

Cleanroom. For. Sterile Manufacturing Facilities

EU GMP Annex 1 Update 2008: Airborne Particle Counting

patient safety A commitment to GE Healthcare

Hospital Pharmacy Automation: Drug Storage and Retrieval

RE: Comments on USP 800 Hazardous Drugs Handling in Healthcare Settings

USP <797> Introduction

USP Chapter <797> Update on Recent Revisions

Raleigh, NC May 12 th & 13 th Meeting The New ISO Cleanroom Standards And Changing EU Guidance How Will You Comply?

Bill Mixon, RPh, MS Senior Associate Gates Healthcare Associates

CLASSIFICATION OF CLEANROOMS

Facility Cleaning & Monitoring. Cleaning

Indiana Pharmacy Inspection Report Questions

Hazardous Drugs Compounded by a Prescriber.

International Standard ISO 14644

7 Deadly Myths of USP 797 Webinar Q&A By Eric Kastango

Open Microphone Meeting:

Infection Control Checklist

CLEAN ROOM MONITORING REGULATORY STANDARDS

ENVIRONMENTAL TESTING & MONITORING: Deciphering Compliance Requirements for Pharmaceutical and Medical Device Manufacturers A WHITE PAPER

DRAFT GUIDANCE. This guidance document is being distributed for comment purposes only.

Design, Operation and Management of GTP/GMP Cell Engineering Facilities

Risk Assessment: Biosafety Cabinet

DISCUSSION TOOL PRESENTED TO THE AABB CT REGULATORY AFFAIRS SUBSECTION

Eric S. Kastango, MBA, RPh, FASHP Clinical IQ, LLC Florham Park, NJ 07932

800 HAZARDOUS DRUGS HANDLING IN HEALTHCARE SETTINGS

2016 > Emcure Pharmaceuticals Limited 3/3/16

Manufacturing. Environmental Monitoring Particle Counts Are Easy B IOP ROCESSTECHNICAL. Scott E. Mackler

Aseptic preparations, including TPN, for a limited number of patients

6/10/2015. MSHP 2015 Compounding CE Event. Practical Pearls on USP <797> and Sterile Compounding. Learning Objectives

Lab Exercise 3: Media, incubation, and aseptic technique

The use of risk assessment tools for microbiological assessment of cleanroom environments. by Tim Sandle

CHAPTER CONSULTING PHARMACIST REGULATIONS FOR LONG-TERM CARE FACILITIES (SKILLED, INTERMEDIATE, AND BASIC CARE)

Healthcare Solutions Room Pressure Monitors and Controls

USP <797> A Road to Compliance The New Mexico Board of Pharmacy

Qualification of Cleanrooms and Environmental Monitoring - Practical Approaches in Europe

TSI BIOTRAK REAL-TIME VIABLE PARTICLE COUNTER FACILITY MONITORING SYSTEMS

Regulations Concerning

BULK WATER HAULING GUIDELINES

GUIDELINES ON TEST METHODS FOR ENVIRONMENTAL MONITORING FOR ASEPTIC DISPENSING FACILITIES

Risk Based Environmental Monitoring (EM) and EM Data Management and Trending

DIALYSIS SPECIFIC EOC OBSERVATION Data Definition Tool

Validating and Monitoring the Cleanroom

Workflow System for Paperless Air Monitoring Powered by MODA. Presented by

General Guide to USP Proposed Chapter <800>: Hazardous Drugs Handling in Healthcare Settings

Sterile operation scenarios at GSK-Parma

GMP ANNEX 1 REVISION 2008, INTERPRETATION OF MOST IMPORTANT CHANGES FOR THE MANUFACTURE OF STERILE MEDICINAL PRODUCTS

Re: Addendum to Preliminary Water Damage Report, Mendocino Public Health Branch, 1120 South Dora Street, Ukiah, CA

Quality Assurance Calendar Laundry and Housekeeping Responsible Party Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec

Checklist for a Physical Containment Level 2 (PC2) Laboratory Facility

Via

MOHD NASRUL MOHAMAD NOOR

Best Practices for Environmental Cleaning for Prevention and Control of Infections In All Health Care Settings: Time for Review

Pharmagraph. GMP/GLP Monitoring System

The proposed chapter is posted online at

The Manitoba Pharmaceutical Association 200 TACHE AVENUE WINNIPEG, MANITOBA R2H 1A7 PHONE (204) FAX (204)

PPG SUPPLIER DEVELOPMENT ASSESSMENT

Aseptic Technique. A GMP/GTP Training Module

MODEL STANDARDS FOR PHARMACY COMPOUNDING OF NON-HAZARDOUS STERILE PREPARATIONS

48 th Annual Meeting. On the Radar: Regulatory Basics. Regulatory Agencies. The Joint Commission. Disclosure. Objectives. The Joint Commission

COMPOUNDING PHARMACY IN THE HOSPITAL SETTING SATURDAY/11:30AM-12:30PM

CHAPTER 17 STERILE PRODUCT COMPOUNDING 17-1

CARE HOMES AND NURSING HOMES

Basic requirements for quality management in plant pest diagnosis laboratories

Arizona State University Institutional Animal Care and Use Committee STANDARD INSTITUTIONAL GUIDELINE RODENT SURGERY

Presentation at the 3 rd SAFOODNET seminar

Design, Construction, Commission, and Qualification of Critical Utility Systems: Part III

cgmp Challenges for Cord Blood Banks

Rutgers Environmental Health and Safety

UW School of Dentistry Comprehensive Medication Policy

Particle Counting and Environmental Monitoring In Pharmaceutical / Life Sciences

Procedures for the Effective Use of Biological Safety Cabinets

Sandoz Private Limited 10/22/15

FMI Listeria Action Plan for Retail Delis

John Keel, CPA State Auditor. An Audit Report on Inspections of Compounding Pharmacies at the Board of Pharmacy. August 2015 Report No.

Biosafety Level 2 (BSL-2) Safety Guidelines

The Environmental Monitoring Program In a GMP Environment

STERILE COMPOUNDING MEDICATION ERRORS OF CONTAMINATION: WHEN TRAGEDY DRIVES CHANGE JULIE STRICKLAND, PHARMD

FS209E and ISO Cleanroom Standards

Clinical Guideline for: Aseptic Technique

Transcription:

USP797: Environmental Testing Plan John Sullivan, Pharm. D. April 11 th, 2015 ISHP Spring Conference Objectives Review requirements for an environmental testing plan Identify areas of opportunity for improvement in sterile compounding practice 1

Why do we need to test? The risk of contaminating a compounded sterile product (CSP) under low-risk level and medium-risk level conditions is highly dependent on proper hand hygiene and garbing practices, compounding personnel aseptic technique, and the presence of surface contamination, assuming that all work is performed in a certified and properly functioning ISO Class 5 primary engineering control (PEC) and secondary engineering controls, ISO Class 7 buffer area, and ISO Class 8 ante-area. High-risk level CSP s pose the greatest threat to patients because compounding personnel are tasked with the requirement of processing non-sterile components and devices in order to achieve sterility. The Why continued A sampling program in conjunction with an observational audit is designed to evaluate the competency of compounding personnel work practices, allowing for the implementation of corrective actions on an ongoing basis. 2

Board of Pharmacy Rules Documentation Requirements - The following documentation must also be maintained by a drug outlet in which sterile products are prepared o Justification of expiration beyond use dates chosen assigned, pursuant to direct testing or extrapolation from reliable literature sources o Training records, evidencing that personnel are trained on a routine basis and are adequately skilled, educated, and instructed o Audits appropriate for the risk of contamination for the particular sterile product including: Visual inspection to ensure the absence of particulate matter in solutions, the absence of leakage from bags and vials, and the accuracy of labeling with each dispensing; Periodic hand hygiene and garbing competency; Media-fill test procedures (or equivalent), aseptic technique, and practice related competency evaluation at least annually by each compounder or sterile prepackager; Board of Pharmacy Rules Environmental sampling testing at least upon registration of a new drug outlet, following the servicing or re-certification of facilities and equipment, or in response to identified problems with end products, staff techniques or patient-related infections, or every six (6) months including: o Total particle counts o Viable air sampling o Gloved fingertip sampling o Surface sampling o Sterility testing of high risk batches of more than twenty-five (25) identical packages before dispensing or distributing o Temperature, logged daily o Beyond use date and accuracy testing, when appropriate o Measuring, mixing, sterilizing, and purification equipment inspection, monitoring, cleaning, and maintenance to ensure accuracy and effectiveness for their intended use. 3

Developing the plan The three areas to monitor: o Air testing Nonviable Viable Air pressures o Surface testing Primary engineering controls (LFH, CAI, CACI, BSC) Buffer area Ante area o Personnel testing Post garbing Within the ISO 5 environment Aseptic manipulation Air testing 4

Nonviable Air Sampling A program to sample nonviable airborne particles differs from that for viable particles in that it is intended to directly measure the performance of the engineering controls used to create the various levels of air cleanliness, for example, ISO Class 5, 7, or 8. Total Particle Counts o Certification that each ISO classified area is within established guidelines. o Performed no less than every 6 months o Performed when PEC s are relocated or the physical structure of the buffer area or ante-area has been altered. o Must be performed by qualified operators using current, state-of-the-art electronic equipment. Allowable Particle Counts ISO Class 5 o Not more than 3520 particles 0.5 µm and larger size per cubic meter of air for any PEC (LAFW, BSC, CAI, and CACI) ISO Class 7 o Not more than 352,000 particle of 0.5 µm and larger per cubic meter of air for any buffer area ISO Class 8 o Not more than 3,520,000 particle of 0.5 µm size and larger per cubic meter of air for any ante-area. 5

Viable Air Sampling An appropriate environmental sampling plan shall be developed for airborne viable particles based on a risk assessment of compounding activities performed. Selected sampling sites shall include locations within each ISO Class 5 environment and in the ISO Class 7 and 8 areas and in the segregated compounding areas at greatest risk of contamination (e.g., work areas near the ISO Class 5 environment, counters near doors, pass-through boxes). How The plan shall include: o Sample location Include greatest risk areas o Method of collection Volumetric collection o 400 to 1000 liters Impaction vs. settling Appropriate growth medium o Soybean-Casein Digest Medium bacteria o Malt extract agar fungi Can be done internally or outsourced o Frequency of sampling At least every 6 months o Documentation o Time of day as related to activity in the compounding area and action levels. Normal activity should be occurring during testing 6

Viable Air Action Levels Classification ISO Class 5 ISO Class 7 ISO Class 8 or worse Air Sample* > 1 CFU > 10 CFU > 100 CFU * CFU per cubic meter [1000 liters] of air per plate. * Any CFU found must be identified at least to the genus level. Pressure Monitoring 3 types o Positive pressure - physical separation (walls, doors, pass-throughs) Monitor for minimum differential positive pressure of 0.02- to 0.05-inch water column. o Displacement airflow (line of demarcation between buffer/ante areas) Monitor air velocity of 40 feet per minute or more across line High risk compounding not allowed o Negative pressure room (HD preparation) Monitor for negative pressure of not less than 0.01-inch water column 7

Surface testing Surface Sampling Surface sampling is an important component of the maintenance of a suitable microbially controlled environment for compounding CSP s., especially since transfer of microbial contamination from improperly disinfected work surfaces via inadvertent touch contact by compounding personnel can be a potential source of contamination into CSP s. It is useful for evaluating facility and work surface cleaning and disinfecting procedures and employee competency in work practices such as disinfection of component/vial surface cleaning. 8

Question Which of the following is incorrect when establishing guidelines for cleaning PEC surfaces? A. Before each batch B. At the beginning of each shift C. Every hour during continuous compounding periods of individual CSP s D. Every 30 minutes during continuous compounding periods of individual CSP s E. When surfaces are visibly soiled How The Plan should include o Locations for surface sampling in all ISO classified areas PEC s Buffer area Ante area o Method of collection Plates containing solid agar growth medium containing lecithin and polysorbate 80 24-30 cm in size o Frequency of sampling USP 797 Periodic basis BOP at least every 6 months o Documentation o Time of sampling o How to address results exceeding acceptable levels 9

Sample Plan Cart Surface Sample Action Levels Classification ISO Class 5 ISO Class 7 ISO Class 8 Surface Sample > 3 CFU > 5 CFU > 100 CFU 10

Personnel testing Gloved Fingertip Sampling All compounding personnel shall successfully complete an initial competency evaluation and gloved fingertip/thumb sampling procedure no less than three times before initially being allowed to compound CSP s for human use. Re-evaluation of all compounding personnel for this competency shall occur at least annually for personnel who compound low- and medium-risk level CSP s and semi-annually for personnel who compound high-risk level CSP s using one or more sample collections during any media-fill test procedure before they are allowed to continue compounding CSP s for human use. 11

Question How often should sterile gloves be disinfected with sterile 70% isopropyl alcohol per USP 797? A. At least every 30 minutes B. Routinely throughout the compounding process C. Only when visibly soiled D. Whenever nonsterile surfaces are touched E. B and D The plan should include o Frequency 3 tests initially USP 797 Annual or semiannual based upon risk level BOP Every 6 months o Method of collection Agar plates containing lecithin and polysorbate 80 o Appropriate garbing procedure Use of 70% isopropyl alcohol on sterile gloves prior to test is prohibited o How to address results exceeding acceptable levels How 12

Fingertip Sample Action Levels Classification ISO Class 5 ISO Class 7 ISO Class 8 Garbingtest (ISO Class 7 or 8) Fingertip Sample > 3 CFU N/A N/A 0 CFU Aseptic Manipulation Competency Evaluation After successful completion of an initial Hand Hygiene and Garbing Competency Evaluation, all compounding personnel shall have their aseptic technique and related practice competency evaluated initially during the media-fill test procedure and subsequent annual or semi-annual media-fill test procedures. Tests should mimic the most challenging or stressful conditions actually encountered by the personnel being evaluated when they prepare low- and medium-risk level CSP s and when sterilizing high-risk level CSP s. 13

The plan should include o Testing kit Selection based upon highest risk level performed at your facility Soybean-Casein Digest medium o Frequency Annually for low- and medium-risk Semi-annually for high-risk o Procedure for test o Documentation o How to address positive test results How Positive Results Positive 14

Processing Samples Request assistance from a laboratory if available Process internally o This will require the purchase of or having access to an incubator Specific temperatures always consult the manufacturers recommendations for the testing product being used o TSA plates should be incubated at 30º to 35º for 48 to 72 hours o Malt extract agar or other suitable fungal media should be incubated at 26º to 30º for 5 to 7 days o Media fill Soybean-Casein Digest medium should be incubated at 20º to 25º or at 30º to 35º for a minimum of 14 days. If using 2 different temperatures ensure that the test is exposed to each temperature for at least 7 days Opportunities for improvement 15

Cleaning ISO Class 5 (PEC) Site Counters and easily cleanable work surfaces Floors Walls Ceilings Storage shelving Minimum Frequency At the beginning of each shift, before each batch, not longer than 30 minutes following the previous surface disinfection when ongoing compounding activities are occurring, after spills, and when surface contamination is known or suspected. Daily Daily Monthly Monthly Monthly Develop processes which result in good habits Identify when items need to be wiped down and wipe them down o Transfer into compounding area o When placed in PEC Have clear processes for garbing and adhere to them o Determine when garb items can be re-used vs. discarded and replaced Develop a cleaning schedule and follow it. Hold yourself and the team accountable o Ensure you educate your peers when slips are observed 16

What can you do better? Remember who is at the end of the process Don t think about taking shortcuts! 17

References United States Pharmacopeal Convention, Inc. <797> Pharmaceutical Compounding Sterile Preparation, United Stated Pharmacopeia 36- National Formulary 31. Rockville, MD: US Pharmacopeal convention, Inc; 2013 Education and Training Negative/Positive photos. Q.I. Medical. Accessed March 7, 2015 http://www.qimedical.com/educationtraining/negative-positive-photos/#prettyphoto/13/ Idaho Code and Administrative Rules 2015 Statute and Rule Changes. Idaho State Board of Pharmacy. February 25, 2015 update. Accessed March 7, 2015 http://bop.idaho.gov/code_rules/ 18